Dupilumab Linked to Higher Food Reaction Risk
A study found pediatric patients had more frequent reactions to food challenges after dupilumab treatment.
Updated on Sept. 30, 2026 in Allergies
Live Poll
Do you trust medical lab results when they contradict a patient's physical symptoms or reactions?
Researchers recently analyzed the records of 129 pediatric patients to evaluate food allergy outcomes following dupilumab treatment. Published on September 24, 2026, the study observed an increase in allergic reactions during oral food challenges among these patients.
Why it matters
This retrospective analysis highlights a potential clinical discrepancy between biological markers, like declining immunoglobulin E levels, and actual physical reactions to food. These findings underscore the importance of ongoing caution when managing food allergies in children treated with this medication.
In a retrospective study of 129 pediatric patients, researchers observed that oral food challenges resulted in a 47.5% reaction rate during or after dupilumab therapy, compared to 20.9% before. Anaphylaxis rates also rose to 25.0% from 9.0% during the study period.
The players
The Journal of Allergy and Clinical Immunology
A medical journal that publishes peer-reviewed research on allergic and immunologic diseases.
The details
Dupilumab works by inhibiting specific proteins that drive inflammation in allergic diseases, which effectively lowered food-specific immunoglobulin E levels by 49% to 89% in the study cohort. Despite these biological improvements, patients showed a threefold increase in the odds of higher severity scores during food challenges. This suggests that the medication may alter the inflammatory response in a way that does not necessarily translate to improved tolerance during oral exposure.
Timeline
November 2014 to November 2024: The period during which patient medical records were reviewed.
September 24, 2026: The study was published in The Journal of Allergy and Clinical Immunology.
Health Landscape
This research complicates the current understanding of how biologic therapies modulate the immune system in pediatric food allergy care. It highlights a departure from the assumption that successful biological suppression of IgE automatically correlates with improved food tolerance.
If you are managing a child's food allergy, discuss these findings and any potential changes in reaction severity with your child's allergist. It is worth confirming that current management and emergency plans remain appropriate regardless of any changes in biological test markers.
The takeaway
While biological therapies may lower certain allergy markers, this study indicates that clinical sensitivity during food challenges can remain high or increase. Always consult with your physician to evaluate how your child responds to treatment rather than relying solely on blood test results.
Further reading
For more context on managing severe sensitivities, visit Allergies.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust medical lab results when they contradict a patient's physical symptoms or reactions?
